September 2011 | Oncology & Biotech News

Insights on Avastin: Patient Selection Is Key

October 18, 2011

The controversy over the breast cancer indication for Avastin culminated in June when the ODAC voted after an unusual and emotional 2-day hearing to uphold a prior recommendation to withdraw the label indication.

The Complexities of Inhibiting Angiogenesis Emerge

October 10, 2011

During the past 40 years, the concept of thwarting a tumor by attacking its blood supply has become a central thrust of cancer research, a strategy that reached a milestone with the approval of bevacizumab in 2004.

Brentuximab Vedotin Proves Effective Against Lymphomas

September 27, 2011

Brentuximab vedotin showed very positive results in lymphoma patients in several early trials, prompting the FDA's Oncologic Drugs Advisory Committee to unanimously recommend accelerated approval for the drug.